Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Globus Medical (GMED)

Globus Medical completes $5.85-per-share cash acquisition of Nevro Corp.

Neutral Impact 4 of 5 m&a Written later

Globus Medical completed its previously announced merger with Nevro Corp. on April 3, 2025, making Nevro a wholly owned subsidiary. Nevro shareholders receive $5.85 per share in cash, and Nevro stock stopped trading on the NYSE before the market opened that day.

Key points

  • Nevro common stock holders receive $5.85 per share in cash, without interest and subject to withholding taxes.
  • Nevro stock options were cancelled without consideration; RSUs and PSUs convert to cash payments at the Merger Consideration.
  • The Merger Agreement is dated February 6, 2025; Globus says the deal unlocks a $2 billion market opportunity in neuromodulation and beyond.
  • Globus plans to discuss the closing and expected benefits on its first quarter earnings conference call in May.

The filing

CompanyGlobus Medical (GMED)
Form8-K, current report
Filed with the SECApr 3, 2025, 9:00 AM ET
Accession number0001193125-25-071923

Items reported: 2.01 Acquisition or Disposition Completed7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 03, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.